Status: Recruiting
Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.
Participants needed: 44
Trial details
Phase: Phase 1, Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Aug 20, 2026Locations: 1
Eligibility criteria
> or = 2 prior lines of therapy (including exposure to at least one proteasome i... [+7]
Active or uncontrolled infection at the start of lymphodepletion and/or cell inf... [+5]